Newsletters - June - 1998

Newsletters - June - 1998

Ocimum sanctum (holy basil), called Tulsi in India, is ubiquitous in Hindu tradition. Perhaps its role as a healing herb was instrumental in its "sacred" implication. Ayurvedic practice recommends Tulsi in several formulations to enhance immunity and metabolic functions as well as in the management of respiratory problems.

A variety of biologically active compounds have been isolated from the leaves including ursolic acid, apigenin and luteolin. Extracts from the plant have been found to reduce stress, modulate immunological functions and retard the development of ulcers in experimental animals1. Ursolic acid, (which is an active constituent in the antioxidant rosemary extract as well), was found to have anti-allergic properties. When administered to laboratory animals, the compound was found to inhibit mast cell degranulation and histamine release in the presence of allergen2. These studies reveal the potential role of Ocimum sanctum extracts in the management of immunological disorders including allergies and asthma. Recent studies also revealed the chemopreventive effects of Tulsi extract3 and the role of the herb in the management of a critical metabolic disorder in recent times - diabetes

A randomized, placebo-controlled cross-over single blind trial on 40 human volunteers suffering from Type II diabetes was performed. During the four week trial, subjects alternately received a daily dose of 2.5 g of Tulsi leaves powder or a placebo for two week periods. The results showed 17.6 % reduction in fasting blood glucose and 7.3% decline in postprandial blood glucose on treatment with Tulsi as compared to the blood glucose levels during treatment with placebo4.

Sabinsa Corporation will supply a dry extract of Ocimum sanctum, standardized for 5% ursolic acid. Please call for further information and samples.

  1. Barghava, K.P and Singh, N. (1981). Ind. J. Med. Res. 73:443-451
  2. Rajasekaran, M. et al. (1989). J. Drug Dev. 2(3):179-182
  3. Banerjee, S. et al. (1996). Nutr. Cancer, 25(2):205-17
  4. Agarwal, P. et al. (1996) Int. J.Clin.Pharmacol. Ther., 34(9):406-9

    VISIT US

  • Sabinsa Europe GmbH
    Monzastrasse 4
    63225 Langen
    Germany

  • +49 6103 270 11 11
  • +49 6103 270 11 27
  • info@sabinsa.eu

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.